MiCAN Technologies

Based in Kyoto, Japan, and established in 2016, MiCAN Technologies Inc. provides immature blood cells to be used for testing. The client can select blood cells and how they are provided from among various options depending on the research objectives (Mpv or Mylc). Kit products, which contain a set of the necessary items for evaluation, are also available. The company also provides various evaluation contract services using high precision blood cell products for drugs and functional materials. Specifically, MiCAN Technologies Inc. provides efficacy evaluation, and safety evaluation. Safety evaluation is done via skin sensitization assay and pyrogen test. In 2017, MiCAN Technologies Inc. developed red blood-like cells for research of infectious diseases (Mpv cells, first product) with Kyoto University and Nagasaki University. In 2018. established a research and development base at Kyoto-University Katsura Venture Plaza. In the same year, submitted a patent application for myeloid cells for research of viruses (Mylc cells, second product) with Osaka University and Kumamoto University., Ltd. In 2020, started collaborative research on COVID-19 virus using Mylc cells with Osaka University. Focusing on viral infections such as COVID-19 and dengue hemorrhagic fever, MiCAN Technologies Inc. will focus on developing a new severity prediction kit that measures the quality of antibodies in the body.

1. Series B

   Aug 7, 2023

   Amount

   $1.4M

   Investors

   Locked

2. Series A

   Sep 16, 2021

   Amount

   $1.7M

   Investors

   Locked

3. Series A

   Aug 23, 2019

   Amount

   $1.2M

   Investors

   Locked